Sarcopenia
Conditions
Brief summary
This study will be the first demonstration of the utility and feasibility of Phosphodiesterase Type 5 inhibitor as an effective pharmacological therapy for improving anabolic resistant states.
Interventions
DRUGTadalafil 5mg
Subjects will ingest one 5mg tablet of tadalafil each evening for 14 days.
Sponsors
University of Arkansas
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
MALE
Age
60 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Ages 60-75 yrs * Recently prescribed 5mg of tadalafil daily for clinical purposes
Exclusion criteria
* History of diabetes * history of hypotension including orthostatic hypotension * History of malignancy or chemo/radiation therapy in the 6 months prior to enrollment * History of short gut syndrome, gastrointestinal bypass/reduction surgery (Lap band, gastric sleeve, etc.) * Subjects who cannot refrain from using protein or amino acid supplements for 7 days prior to Visit 2 and 3. * Alcohol consumption of ≥ 5 units/servings per day * Concomitant use of * oral or injectable corticosteroids * testosterone, insulin like growth factor-1, or similar anabolic agent * riociguat (Adempas) * nitroglycerin * isosorbide dinitrate (Isordil) * isosorbide mononitrate (Imdur, Monoket) * doxazosin (Cardura) * prazosin (Minipress) * terazosin (Hytrin) * Any other disease or condition that would place the subject at increased risk of harm if they were to participate, at the discretion of the study physician
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in maximal voluntary contraction of lower leg. | 14 days | Lower leg strength using a dynamometer; performed both before and after 14 days of tadalafil |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in muscle Fatigue | 14 days | A test of lower leg muscular endurance using a dynamometer; performed both before and after 14 consecutive days of tadalafil. |
Countries
United States
Outcome results
None listed